269 related articles for article (PubMed ID: 18927431)
81. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
82. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
[TBL] [Abstract][Full Text] [Related]
83. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
[TBL] [Abstract][Full Text] [Related]
84. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.
Barish GD; Yu RT; Karunasiri MS; Becerra D; Kim J; Tseng TW; Tai LJ; Leblanc M; Diehl C; Cerchietti L; Miller YI; Witztum JL; Melnick AM; Dent AL; Tangirala RK; Evans RM
Cell Metab; 2012 Apr; 15(4):554-62. PubMed ID: 22465074
[TBL] [Abstract][Full Text] [Related]
85. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
[TBL] [Abstract][Full Text] [Related]
86. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Aman P; Cavallin-Stahl E; Torlakovic E; Akerman M; Mitelman F; Fioretos T
Int J Oncol; 2002 Jan; 20(1):161-5. PubMed ID: 11743658
[TBL] [Abstract][Full Text] [Related]
87. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
88. Analysis of BCL6-interacting proteins by tandem mass spectrometry.
Miles RR; Crockett DK; Lim MS; Elenitoba-Johnson KS
Mol Cell Proteomics; 2005 Dec; 4(12):1898-909. PubMed ID: 16147992
[TBL] [Abstract][Full Text] [Related]
89. Achieving
Bellenie BR; Cheung KJ; Varela A; Pierrat OA; Collie GW; Box GM; Bright MD; Gowan S; Hayes A; Rodrigues MJ; Shetty KN; Carter M; Davis OA; Henley AT; Innocenti P; Johnson LD; Liu M; de Klerk S; Le Bihan YV; Lloyd MG; McAndrew PC; Shehu E; Talbot R; Woodward HL; Burke R; Kirkin V; van Montfort RLM; Raynaud FI; Rossanese OW; Hoelder S
J Med Chem; 2020 Apr; 63(8):4047-4068. PubMed ID: 32275432
[TBL] [Abstract][Full Text] [Related]
90. Structure of the wild-type human BCL6 POZ domain.
Stead MA; Rosbrook GO; Hadden JM; Trinh CH; Carr SB; Wright SC
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 Dec; 64(Pt 12):1101-4. PubMed ID: 19052359
[TBL] [Abstract][Full Text] [Related]
91. B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.
Gu H; He J; Li Y; Mi D; Guan T; Guo W; Liu B; Chen Y
J Med Chem; 2022 Dec; 65(23):15559-15583. PubMed ID: 36441945
[TBL] [Abstract][Full Text] [Related]
92. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
Mensah AA; Spriano F; Sartori G; Priebe V; Cascione L; Gaudio E; Tarantelli C; Civanelli E; Aresu L; Rinaldi A; Damia G; Lovati E; Zucca E; Stathis A; Pietra C; Bertoni F
Blood Adv; 2021 May; 5(10):2467-2480. PubMed ID: 33999145
[TBL] [Abstract][Full Text] [Related]
93. A peptide aptamer to antagonize BCL-6 function.
Chattopadhyay A; Tate SA; Beswick RW; Wagner SD; Ko Ferrigno P
Oncogene; 2006 Apr; 25(15):2223-33. PubMed ID: 16331266
[TBL] [Abstract][Full Text] [Related]
94. B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
McLachlan T; Matthews WC; Jackson ER; Staudt DE; Douglas AM; Findlay IJ; Persson ML; Duchatel RJ; Mannan A; Germon ZP; Dun MD
Mol Cancer Res; 2022 Dec; 20(12):1711-1723. PubMed ID: 36166198
[TBL] [Abstract][Full Text] [Related]
95. Backbone resonance assignment of the BCL6-BTB/POZ domain.
Lin LY; Evans SE; Fairall L; Schwabe JWR; Wagner SD; Muskett FW
Biomol NMR Assign; 2018 Apr; 12(1):47-50. PubMed ID: 28929458
[TBL] [Abstract][Full Text] [Related]
96. Discovery of an
Harnden AC; Davis OA; Box GM; Hayes A; Johnson LD; Henley AT; de Haven Brandon AK; Valenti M; Cheung KJ; Brennan A; Huckvale R; Pierrat OA; Talbot R; Bright MD; Akpinar HA; Miller DSJ; Tarantino D; Gowan S; de Klerk S; McAndrew PC; Le Bihan YV; Meniconi M; Burke R; Kirkin V; van Montfort RLM; Raynaud FI; Rossanese OW; Bellenie BR; Hoelder S
J Med Chem; 2023 Apr; 66(8):5892-5906. PubMed ID: 37026591
[TBL] [Abstract][Full Text] [Related]
97. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
Nat Med; 2009 Dec; 15(12):1369-76. PubMed ID: 19966776
[TBL] [Abstract][Full Text] [Related]
98. Alternative splicing generates a short BCL6 (BCL6S) isoform encoding a compact repressor.
Shen Y; Ge B; Ramachandrareddy H; McKeithan T; Chan WC
Biochem Biophys Res Commun; 2008 Oct; 375(2):190-3. PubMed ID: 18675787
[TBL] [Abstract][Full Text] [Related]
99. Rewiring cancer drivers to activate apoptosis.
Gourisankar S; Krokhotin A; Ji W; Liu X; Chang CY; Kim SH; Li Z; Wenderski W; Simanauskaite JM; Yang H; Vogel H; Zhang T; Green MR; Gray NS; Crabtree GR
Nature; 2023 Aug; 620(7973):417-425. PubMed ID: 37495688
[TBL] [Abstract][Full Text] [Related]
100. Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination.
Park HY; Go H; Song HR; Kim S; Ha GH; Jeon YK; Kim JE; Lee H; Cho H; Kang HC; Chung HY; Kim CW; Chung DH; Lee CW
J Clin Invest; 2014 Nov; 124(11):4976-88. PubMed ID: 25295537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
